Specialist diagnostics partner in the Benelux
+31 (0)85 0045479 Mon–Fri 08:30–17:00 · -
Oncology & Haematology · BRAF
TruPCR Distributed by Goffin Diagnostics

Colorectal Cancer Mutation Panel Kit

The TruPCR Colorectal Mutation Panel detects hotspot mutations in KRAS, NRAS and BRAF by multiplex real-time PCR, on genomic DNA from formalin-fixed paraffin-embedded, fresh or frozen tumour tissue. The mutation status of these three genes determines treatment in metastatic colorectal cancer: a mutation in KRAS or NRAS predicts a lack of response to anti-EGFR antibodies, and BRAF p.V600E marks a subgroup with its own prognosis and its own treatment combination.

Real-Time PCR CE-IVD TruPCR 1 Unit (24 Reactions), 1 Unit (48 Reactions)
Technique
Real-Time PCR
Brand
TruPCR
Packaging
1 Unit (24 Reactions), 1 Unit (48 Reactions)
Download documentation

Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.

Product details

This kit in detail

  • Hotspot mutations in KRAS, NRAS and BRAF in one panel
  • Multiplex real-time PCR with internal controls
  • FFPE, fresh or frozen tumour tissue
  • Determines eligibility for anti-EGFR treatment
  • 24 or 48 reactions per kit, REF 3B1413 and 3B1414

The TruPCR Colorectal Mutation Panel determines the RAS and BRAF mutation status of a colorectal tumour, the result that decides which systemic treatment is an option.

Clinical background

KRAS, NRAS and BRAF encode proteins in the RAS-RAF-MEK-ERK pathway downstream of the EGFR receptor. An activating mutation keeps that pathway switched on regardless of the receptor, which is why patients with a KRAS or NRAS mutation do not benefit from cetuximab or panitumumab. BRAF p.V600E defines a subgroup with a poorer prognosis, treated with a different combination.

Method and sample

Multiplex real-time PCR on genomic DNA from formalin-fixed paraffin-embedded, fresh or frozen tumour tissue. The reagents and internal controls needed are included, and the manufacturer states validation on the common real-time PCR platforms.

What the manufacturer does not specify

The catalogue names the three genes but no codons, exons or mutation count, and gives no limit of detection for the mutant fraction. For a tumour assay both figures matter, so they are not claimed here.

Documentation

Datasheets and regulatory documentation

Everything your quality team needs for evaluation and procurement.

Let’s talk diagnostics

Add this kit to your quote

Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.